PR US CRM Iperia FDA Approval EN, 151204
PR CRM In-Time Study EN, 140507
BIOTRONIK's Orsiro Mission Drug-Eluting Stent | Medgadget PR US CRM Eluna FDA Approval, 150401
PR CRM Scientific Session Cardiostim 2016 EN, 160608
PDF CORONARY STENT - KHManipal PR CRM E-Series CE Mark EN, 140327
The latest generation of BIOTRONIK's DES, Orsiro® Mission gained FDA approval in 2021 and benefits from the same stent as its predecessor device with a reengineered delivery system for even. PR CRM B3 study EN, 151201
P-I, BIOLUX
PR Company Spendenuebergabe St. Augustin DE, 160801
T3, AlCath
PR JP CRM Iperia ProMRI Launch JP, 150907
PR CRM Sentus QP ProMRI DE, 141124
2, BIOMONITOR
.Indication-Image {float:right} The information provided in this section is intended exclusively for healthcare professionals in countries where the products have been approved by the competent authorities. PR CRM ProMRI HRS 2015 EN, 150513
Software, Recent
.Pre-Header { PR VI BIOLUX P-III study EN, 141024
BIOTRONIK won the European CE Mark for its Orsiro Mission drug-eluting stent. Flutter Gold, AlCath
BIOTRONIK is a leading global medical technology company with products and services that save and improve the lives of millions suffering from heart and blood vessel diseases as well as chronic pain. Women, BIO
Failure, Atrial
Our unique revolutionary innovations and technology span cardiac rhythm management, vascular intervention and electrophysiology. PR CRM Home Monitoring Cardiostim 2014 DE, 140616
PR VI BIOHELIX II study EN, 141202
Nochmals verbesserte Platzierbarkeit des herausragenden Orsiro-Stents. PR US CRM Itrevia HF-T QP EN, 150702
Patient Story Detlef Günther EN, 2016
7 HF-T QP/HF-T, Itrevia
vertical-align: middle; text-align:center;} PR VI BIOSOLVE-II DE, 150217
People, Director
PR Zero Gravity CE Mark EN, 140923
Bipolar Pacing Catheter, Qubic
PR VI Magmaris 1000 EN, 170320
Our innovations enable care that saves and improves the lives of patients diagnosed with heart and blood vessel diseases. Kandzari D et al. PR CRM CardioMessenger Smart CE EN, 150504
Pulsar, Passeo-18
} Synsiro is a hybrid DES solution consisting of passive and active components: PR VI Pulsar-18 EN, 140522
Kandzari D et al. BIOTRONIK is headquartered in Berlin, Germany, and is represented in over 100 countries. PR Company Patient Day 2015 EN, 150615
AFFIRM, ProMRI
PR UK CRM CLS Symposium HRC 2016 EN, 160929
text-decoration: none; .Downloads {display:none;} /* Hide */
SLENDER Sirolimus-Eluting Coronary Stent Integrated Delivery System and ... PR US CRM Care Beyond the Implant EN, 160420
5 VR-T/VR-T DX/DR-T, Inlexa
PR Company Spenden Kaeltehilfe DE, 160303
We produce a full range of stent systems, balloon catheters and guide wires for patients with coronary and peripheral artery disease. } 3 DR-T/VR-T, Inventra
*Clinical data conducted with Orsiro, Orsiro Mission’s predecessor device can be used to illustrate Orsiro Mission clinical outcomes. PR US CRM Eluna ProMRI, 150512
To Join BIOTRONIK, Our
D II, TASC
3 HF-T QP/HF-T, Inventra
Synsiro Pro | Biotronik PR US CRM ProMRI ACC 2015 EN, 150303
4, TASC
PR ES VI CIRSE 2016 EN, 160912
& Education, Social
Driven by a purpose to perfectly match technology with the human body, we are dedicated innovators who develop trusted cardiovascular, endovascular and neuromodulation solutions. PR US ProMRI Phase C EN, 150120
PR VI BIOFLEX PEACE EN, 161107
PR CRM BioMonitor 2 ESC 2015 EN, 150827
If the stent cannot be deployed, the entire system and the guiding catheter should be removed as one unit; do not attempt to retrieve the stent back through the guiding catheter; dislodgment of the stent may result. The BIOlute® active component is a bioabsorbable polymer matrix combined with an anti-proliferative drug, sirolimus, that is released in a controlled manner leaving only the PROBIO® coated stent in the long-term. Cliccando i link sottostanti accederai alle news del nostro sito web Internazionale, stai lasciando il sito web Italiano. PR CRM E-Series CE Mark DE, 160617
Arterial Disease (PAD), Coronary
PR VI BIOSOLVE II study EN, 151013
PR VI Great Minds Magmaris DE, 160616
PR US CRM Edora CR-T, 170330
BIOTRONIK's Ultrathin Strut Orsiro Coronary Drug-Eluting Stent Continues to Deliver Excellent Results after Three Years READ MORE NewsRoom 1. PR CRM ProMRI AFFIRM EN, 150204
8 HF-T, Entovis
5 Iglesias JF et al. Energy, Pantera
PR CRM B3 study EN, 151201
PR US CRM ProMRI Phase B Study EN, 141202
PR EP Qubic Stim Cardiostim DE, 140613
PR US CRM BioInsight Study EN, 161121
Equipment, Working
The BIOTRONIK BIOFLOW-V clinical trial is a prospective, multicenter, randomized, controlled trial combining data on the randomized subjects with data from two historical studies by employing a Bayesian approach. Synsiro Pro | Biotronik Vaskuläre Intervention // Koronar Medikamentfreisetzendes Stentsystem Synsiro Pro Nochmals verbesserte Platzierbarkeit des herausragenden Orsiro-Stents. Life, Further
Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents versus Thin Durable Polymer Everolimus-Eluting Stents in Patients Undergoing Coronary Revascularisation (BIOFLOW-V): a randomized trial, 2017, Iglesias JF et al. At two years, treatment with Orsiro further improved event rates in comparison to Xience, including a significant reduction in target lesion revascularization (TLR) and spontaneous MI. /* STYLES FOR BIGGER SCREENS >600px */ PR US VI BIOFLEX-I study EN, 150219
PR CRM CardioMessenger Smart CE EN, 150504
PR VI BIOSOLVE II study EN, 151013
.Row {
BIOTRONIK today announced FDA approval of the Orsiro drug-eluting stent (DES) system. With Orsiro’s clinical program clinicians can be sure when they choose the Orsiro Mission DES they are choosing an implant with extensive evidence. DR-T/SR-T, Effecta
7 HF-T QP/HF-T, Ilivia
PR CRM ProMRI ESC 2015 EN, 150825
Neo 7 VR-T/VR-T DX/DR-T, Intica
The Orsiro® Mission Sirolimus Eluting Coronary Stent System (stent) is a drug-eluting balloon-expandable stent. Published online: September 2, 2019. 5 DR-T/VR-T, Iforia
PR US CRM Inventra Launch EN, 161101
6 DR-T/SR-T, Enitra
PR HBI Opening Heart Center EN, 151202
Arterial Disease, Cardiac
PR US CRM ProMRI HRJ EN, 150615
} PR CRM BIOCONTINUE study DE, 150728
Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. .Indication { PR CRM Sentus QP ProMRI EN, 141201
[CDATA[/* >